$OV #Medical Prognosis Institute A/S Oncology Venture - Company consolidates ownership of dovitinib: Oncology Venture (OV) announced on 8 June 2020 that it acquired the remaining 37% minority stake in its dovitinib asset for SEK36m in… https://t.co/YfkaA9x6JZ #equity #stocks https://t.co/x9ll3GeXFM